Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medivation has reported that clinical results from its first pivotal trial of Dimebon showed that behavioral symptoms were stabilized in patients with mild-to-moderate Alzheimer's disease over a one-year period, resulting in decreased caregiver distress.
Subscribe to our email newsletter
Benefits of Dimebon were seen across most behavioral symptoms and were most prominent in the symptoms of depression, apathy, hallucinations, irritability and motor disturbance.
The presented data included the results of an analysis of the 12 subdomains of the Neuropsychiatric Inventory (NPI), a measure of the behavioral symptoms of Alzheimer’s disease (AD). During the study, the NPI was assessed at the beginning of the study and at weeks 12, 26, 39 and 52. Results showed that Dimebon-treated patients were significantly improved on the NPI total score compared with placebo-treated patients after six months (p=0.01) and one year of treatment (p=0.04). Dimebon treatment resulted in improvement over placebo on eight of the 12 individual NPI subdomains.
Importantly, the behavioral improvements from Dimebon treatment resulted in a significant decrease in caregiver distress at six months (p=0.004) and at one year (p=0.04), compared to the distress of placebo patients caregivers.